Literature DB >> 11934227

Targeting vaccines to dendritic cells.

Camilla Foged1, Anne Sundblad, Lars Hovgaard.   

Abstract

Dendritic cells (DC) are specialized antigen presenting cells (APC) with a remarkable ability to take up antigens and stimulate major histocompatibility complex (MHC)-restricted specific immune responses. Recent discoveries have shown that their role in initiating primary immune responses seems to be far superior to that of B-cells and macrophages. DC are localized at strategic places in the body at sites used by pathogens to enter the organism, and are thereby in an optimal position to capture antigens. In general, vaccination strategies try to mimic the invasiveness of the pathogens. DC are considered to play a central role for the provocation of primary immune responses by vaccination. A rational way of improving the potency and safety of new and already existing vaccines could therefore be to direct vaccines specifically to DC. There is a need for developing multifunctional vaccine drug delivery systems (DDS) with adjuvant effect that target DC directly and induce optimal immune responses. This paper will review the current knowledge of DC physiology as well as the progress in the field of novel vaccination strategies that directly or indirectly aim at targeting DC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934227     DOI: 10.1023/a:1014474414097

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  61 in total

Review 1.  Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies.

Authors:  R M Steinman; K Inaba; S Turley; P Pierre; I Mellman
Journal:  Hum Immunol       Date:  1999-07       Impact factor: 2.850

2.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

Authors:  A Rodriguez; A Regnault; M Kleijmeer; P Ricciardi-Castagnoli; S Amigorena
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

3.  Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector.

Authors:  B W Tillman; T D de Gruijl; S A Luykx-de Bakker; R J Scheper; H M Pinedo; T J Curiel; W R Gerritsen; D T Curiel
Journal:  J Immunol       Date:  1999-06-01       Impact factor: 5.422

4.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

Authors:  S K Nair; D Boczkowski; M Morse; R I Cumming; H K Lyerly; E Gilboa
Journal:  Nat Biotechnol       Date:  1998-04       Impact factor: 54.908

5.  CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis.

Authors:  C Caux; C Massacrier; B Vanbervliet; B Dubois; I Durand; M Cella; A Lanzavecchia; J Banchereau
Journal:  Blood       Date:  1997-08-15       Impact factor: 22.113

6.  Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin.

Authors:  A Tang; M Amagai; L G Granger; J R Stanley; M C Udey
Journal:  Nature       Date:  1993-01-07       Impact factor: 49.962

7.  The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.

Authors:  N Haicheur; E Bismuth; S Bosset; O Adotevi; G Warnier; V Lacabanne; A Regnault; C Desaymard; S Amigorena; P Ricciardi-Castagnoli; B Goud; W H Fridman; L Johannes; E Tartour
Journal:  J Immunol       Date:  2000-09-15       Impact factor: 5.422

8.  Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.

Authors:  M Kovacsovics-Bankowski; K Clark; B Benacerraf; K L Rock
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.

Authors:  B Sauter; M L Albert; L Francisco; M Larsson; S Somersan; N Bhardwaj
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

10.  Prevention of peripheral tolerance by a dendritic cell growth factor: flt3 ligand as an adjuvant.

Authors:  B Pulendran; J L Smith; M Jenkins; M Schoenborn; E Maraskovsky; C R Maliszewski
Journal:  J Exp Med       Date:  1998-12-07       Impact factor: 14.307

View more
  18 in total

1.  Transgene expression and local tissue distribution of naked and polymer-condensed plasmid DNA after intradermal administration in mice.

Authors:  R Noelle Palumbo; Xiao Zhong; David Panus; Wenqing Han; Weihang Ji; Chun Wang
Journal:  J Control Release       Date:  2012-01-24       Impact factor: 9.776

2.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

3.  Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles.

Authors:  Hong Shen; Anne L Ackerman; Virginia Cody; Alessandra Giodini; Ella R Hinson; Peter Cresswell; Richard L Edelson; W Mark Saltzman; Douglas J Hanlon
Journal:  Immunology       Date:  2006-01       Impact factor: 7.397

Review 4.  Nanocarriers targeting dendritic cells for pulmonary vaccine delivery.

Authors:  Nitesh K Kunda; Satyanarayana Somavarapu; Stephen B Gordon; Gillian A Hutcheon; Imran Y Saleem
Journal:  Pharm Res       Date:  2012-10-09       Impact factor: 4.200

5.  Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly.

Authors:  Nhat-Long L Pham; Lecia L Pewe; Courtney J Fleenor; Ryan A Langlois; Kevin L Legge; Vladimir P Badovinac; John T Harty
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

6.  Polymer-mediated DNA vaccine delivery via bystander cells requires a proper balance between transfection efficiency and cytotoxicity.

Authors:  R Noelle Palumbo; Xiao Zhong; Chun Wang
Journal:  J Control Release       Date:  2011-09-01       Impact factor: 9.776

7.  Transdermal immunization of P. falciparum surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity.

Authors:  Rajeev K Tyagi; Neeraj K Garg; Sarat K Dalai; Amit Awasthi
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

8.  Novel Injectable Pentablock Copolymer Based Thermoresponsive Hydrogels for Sustained Release Vaccines.

Authors:  Sharan Bobbala; Viral Tamboli; Arlene McDowell; Ashim K Mitra; Sarah Hook
Journal:  AAPS J       Date:  2015-11-20       Impact factor: 4.009

Review 9.  Nanoparticle delivery systems in cancer vaccines.

Authors:  Yogita Krishnamachari; Sean M Geary; Caitlin D Lemke; Aliasger K Salem
Journal:  Pharm Res       Date:  2010-08-19       Impact factor: 4.580

10.  Nanoliposomes of L-lysine-conjugated poly(aspartic acid) Increase the Generation and Function of Bone Marrow-derived Dendritic Cells.

Authors:  Sun-A Im; Ki-Hyang Kim; Hong-Geun Ji; Hyoung-Gyoung Yu; Sun-Ki Park; Chong-Kil Lee
Journal:  Immune Netw       Date:  2011-10-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.